Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/Visilizumab> ?p ?o }
Showing triples 1 to 61 of
61
with 100 triples per page.
- Visilizumab abstract "Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons. Nevertheless, clinical trials continue for various diseases like multiple myeloma and diabetes mellitus type 1 as of July 2009.Visilizumab has also been radiolabelled with technetium-99m for imaging T cells.".
- Visilizumab atcPrefix "none".
- Visilizumab wikiPageID "9134442".
- Visilizumab wikiPageLength "3833".
- Visilizumab wikiPageOutDegree "13".
- Visilizumab wikiPageRevisionID "640822266".
- Visilizumab wikiPageWikiLink CD3_(immunology).
- Visilizumab wikiPageWikiLink CD3_receptor.
- Visilizumab wikiPageWikiLink Category:Monoclonal_antibodies.
- Visilizumab wikiPageWikiLink Clinical_trial.
- Visilizumab wikiPageWikiLink Clinical_trials.
- Visilizumab wikiPageWikiLink Crohns_disease.
- Visilizumab wikiPageWikiLink Diabetes_mellitus_type_1.
- Visilizumab wikiPageWikiLink Humanized_antibody.
- Visilizumab wikiPageWikiLink Humanized_monoclonal_antibody.
- Visilizumab wikiPageWikiLink Immunosuppressive_drug.
- Visilizumab wikiPageWikiLink Isotopic_labeling.
- Visilizumab wikiPageWikiLink Multiple_myeloma.
- Visilizumab wikiPageWikiLink Radiolabel.
- Visilizumab wikiPageWikiLink T_cell.
- Visilizumab wikiPageWikiLink Technetium-99m.
- Visilizumab wikiPageWikiLink Ulcerative_colitis.
- Visilizumab wikiPageWikiLinkText "Nuvion".
- Visilizumab wikiPageWikiLinkText "Visilizumab".
- Visilizumab wikiPageWikiLinkText "visilizumab".
- Visilizumab atcPrefix "none".
- Visilizumab chemspiderid "NA".
- Visilizumab hasPhotoCollection Visilizumab.
- Visilizumab mabType "mab".
- Visilizumab source "zu/o".
- Visilizumab target CD3_(immunology).
- Visilizumab target CD3_receptor.
- Visilizumab type "mab".
- Visilizumab verifiedrevid "470631023".
- Visilizumab wikiPageUsesTemplate Template:Antineoplastic-drug-stub.
- Visilizumab wikiPageUsesTemplate Template:As_of.
- Visilizumab wikiPageUsesTemplate Template:Drugbox.
- Visilizumab wikiPageUsesTemplate Template:Immunosuppressants.
- Visilizumab wikiPageUsesTemplate Template:Monoclonal-antibody-stub.
- Visilizumab wikiPageUsesTemplate Template:Monoclonals_for_immune_system.
- Visilizumab wikiPageUsesTemplate Template:Reflist.
- Visilizumab subject Category:Monoclonal_antibodies.
- Visilizumab hypernym Antibody.
- Visilizumab type Article.
- Visilizumab type ChemicalSubstance.
- Visilizumab type Drug.
- Visilizumab type Antibody.
- Visilizumab type Article.
- Visilizumab type Chemical.
- Visilizumab type Drug.
- Visilizumab type ChemicalObject.
- Visilizumab type Thing.
- Visilizumab type Q8386.
- Visilizumab comment "Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.PDL BioPharma, Inc.".
- Visilizumab label "Visilizumab".
- Visilizumab sameAs Wizylizumab.
- Visilizumab sameAs m.027yz3r.
- Visilizumab sameAs Q7936102.
- Visilizumab sameAs Q7936102.
- Visilizumab wasDerivedFrom Visilizumab?oldid=640822266.
- Visilizumab isPrimaryTopicOf Visilizumab.